Legend Biotech (LEGN) EBIT (2019 - 2026)

Legend Biotech (LEGN) has 8 years of EBIT data on file, last reported at -$49.8 million in Q1 2026.

• Quarterly EBIT rose 3.68% year-over-year to -$49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.1 million (up 102.9% YoY) and the FY2025 annual result came in at -$136.5 million, up 55.9% from the prior year.
• EBIT declined to -$49.8 million in Q1 2026, from -$19.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $79.4 billion in Q4 2023 to a low of -$189.3 million in Q2 2022.
• A 5-year average of $4.7 billion and a median of $107.8 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT plunged 58501.13% — and 2023, when it surged 70754.09%.
• Tracing LEGN's EBIT over 5 years: stood at $112.1 million in 2022, then surged by 70754.09% to $79.4 billion in 2023, then sank by 100.1% to -$79.3 million in 2024, then soared by 75.16% to -$19.7 million in 2025, then sank by 152.79% to -$49.8 million in 2026.
• The last three EBIT figures came in at -$49.8 million (Q1 2026), -$19.7 million (Q4 2025), and -$43.5 million (Q3 2025), per Business Quant data.